Loading clinical trials...
Loading clinical trials...
Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Technische Universität Dresden
Dresden, Germany
Start Date
April 25, 2025
Primary Completion Date
April 1, 2029
Completion Date
April 1, 2030
Last Updated
May 29, 2025
60
ESTIMATED participants
Gilteritinib (GILT)
DRUG
Venetoclax (VEN)
DRUG
Azacitidine (AZA)
DRUG
Lead Sponsor
Technische Universität Dresden
NCT06994676
NCT06782971
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07201727